NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity ...

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close.

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...